Nguyen Tran, MD
Allergy & Immunology · Overland Park, KSNPI 1558578476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 787 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.
Across 787 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- CSL Behring$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$953
- Takeda Pharmaceuticals U.S.A., Inc.$799
- plus $6K from 29 others
What the payments were for
- Consulting fees$1531%
- Food & beverage$14,69899%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 160 | $3,113 |
| CSL Behring | 67 | $1,490 |
| GSK | 73 | $1,202 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,156 |
| Genentech USA, Inc. | 54 | $953 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $799 |
| Novartis | 43 | $729 |
| Sanofi | 34 | $717 |
| Pfizer | 32 | $473 |
| Pharming Healthcare, Inc. | 22 | $466 |
| AbbVie | 31 | $445 |
| Grifols USA, LLC | 21 | $410 |
| Hospira, Inc. | 28 | $403 |
| Amgen(2 entities) | 17 | $335 |
| Bio Products Laboratory USA, Inc. | 14 | $257 |
| LEO Pharma Inc. | 13 | $250 |
| Optinose US, Inc. | 9 | $215 |
| Lilly USA, LLC | 11 | $206 |
| Incyte Corporation | 4 | $173 |
| ADMA Biomanufacturing LLC | 8 | $153 |
| Boehringer Ingelheim | 9 | $149 |
| Biocryst US Sales Co., LLC | 6 | $125 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $93 |
| Kaleo, Inc. | 5 | $92 |
| Octapharma USA, Inc. | 4 | $77 |
| Sunovion Pharmaceuticals Inc. | 3 | $64 |
| Hikma Pharmaceuticals USA | 3 | $59 |
| Alk-abello, Inc | 3 | $58 |
| Blueprint Medicines Corporation | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Merck | 1 | $18 |
| GC Biopharma USA, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,873 in reported general payments places this provider in the 80th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $56,186 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $23,435 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $21,282 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,495 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $4,994 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $4,619 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,391 |
| Azelastine Hcl | 130 | $4,207 |
| Ipratropium Bromide | 67 | $2,553 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,428 |
| Epinephrine | 17 | $1,901 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $1,894 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 14 | $1,751 |
| Montelukast Sodium | 171 | $1,499 |
| Fluticasone Propionate | 55 | $1,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,202 | $72,110122 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,113 | $25,67348 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $799 | $23,43511 claims |
| Hikma Pharmaceuticals USAEpinephrine | $59 | $1,90117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Overland Park
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
- William LaveryOverland Park$25K
- Sara AzzamOverland Park$19K
- Cori PasserOverland Park$14K
- Derrick WardOverland Park$6K
- Mark NeustromOverland Park$3K
- James SternerOverland Park$3K
- H LevineOverland Park$3K
- Khaled GirgisOverland Park$636
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.